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Objectives. To identify if carotid stent design, especially free cell area, impacts on the 30-day rates for stroke, death and
TIA after carotid artery stenting (CAS).
Material and methods. A CAS database of 3179 consecutive CAS patients was retrospectively assessed. The distribution
of neurological complications were analysed for association with the different stent types and designs. Events where
subdivided into procedural and postprocedural events.
Results. The overall combined rate of TIA, stroke and death was 2.8% at 30 days (late events 1.9%). The post-procedural
event rate analyzed for differences stents varied from 1.2% using BSCI Carotid Wallstent to 5.9% using Medtronic
Exponent. The late event rates varied from 1.2% to 3.4% for free cell areas <2.5 mm2 and >7.5 mm2 respectively
(p< 0.05). Post-procedural event rate was 1.3% for closed cells and 3.4% for open cells. All these differences were highly
pronounced among symptomatic patients (p< 0.0001).
Conclusions. After carotid stenting, complication rates vary according to stent type, free cell area and cell design. In the
symptomatic population (and also in the total population), post-procedural complication rates are highest for the open cell
types and increase with larger free cell area.
Keywords: Carotid artery stenting; Carotid stenosis; Neurological complications; Cell design; Free cell area; Late embolic
events.Introduction
Carotid angioplasty and stenting (CAS) is increas-
ingly used in the treatment of severely stenotic carotid
disease.1e4 With growing experience and the intro-
duction of dedicated CAS materials, recent research
showed that in high volume centers, there has been
a shift from intra- to post-procedural complications.5
Approximately 2/3 all events occurred after the pro-
cedure, which are probably caused by late emboli
through the struts of the stent. During carotid endar-
terectomy (CEA) the complete plaque is removed.
With carotid stenting the plaque remains contained
in between the stent and the vessel wall. The stent
needs to offer sufficient scaffolding in order to pre-
vent post-procedural plaque embolization through
the stent struts. Logically stents with a smaller free
*Corresponding author. M. Bosiers, MD, Department of Vascular
Surgery, AZ St-Blasius, Kroonveldlaan 50, 9200 Dendermonde,
Belgium.
E-mail address: marc.bosiers@telenet.be1078–5884/000135+ 07 $32.00/0  2006 Elsevier Ltd. All rights resecell area and hence a greater percentage of wall cover-
age may better contain the fractured and dilated
plaque after CAS resulting in a lower number of
post-procedural events.
To investigate this hypothesis we reviewed the 30
day outcome after CAS in four centers with high
volume experience, excluding the bias of the learning
curve.
Materials and Methods
Patients
3281 patients were scheduled to undergo percutane-
ous carotid revascularization of the internal carotid
artery in the Department of Vascular Surgery of the
AZ St-Blasius in Dendermonde, Belgium, in the
Department of Cardiovascular and Thoracic Surgery
of the Imelda Hospital in Bonheiden, Belgium, in
the Department of Vascular and Endovascular Sur-
gery,University of Siena, Italy, and in the Interventionalrved.
136 M. Bosiers et al.Cardio-Angiology Unit, Villa Maria Cecilia Hospital,
Cotignola, Italy. The interventionalists at the different
sites all had an experience of over 50CAS before the da-
tabases were set-up in their services.
In 11 out of 3281 patients (0.35%), CAS could not be
performed due to unsuccessful common carotid
engagement or embolic protection device delivery or
deployment, all were converted to CEA. 91 where left
out of the analysis because only a small number of
procedures where done with these devices (Palmaz e
Cordis n¼ 12, Symbiott - Boston Scientific n¼ 1,
Conformexx - Bard n¼ 3, Memotherm - Bard n¼ 1,
Vivexx - Bard n¼ 6) or the device was never commer-
cially available (Zilver - Cook n¼ 37), or the treatment
consisted only in angioplasty (n¼ 31).
The remaining 3179 patients were available for
analysis, including 1317 (41.4%) patients with symp-
tomatic disease and 1862 (58.6%) patients with
asymptomatic disease. A demographic analysis of
all subgroups was performed (Table 1), showing no
difference in the presence of any specific risk factors
in any of the investigated stent groups.
CAS was performed via each unit’s existing stan-
dards of care as described previously.6e9 Protected
CAS with an embolic protection device (EPD) was
performed in 3049 patients (95.9%): distal filtrations
systems were used in 2831 (92.9%) [FilterWire - Boston
Scientific, Angioguard - Cordis, Accunet - Guidant,
Emboshield - Abbott Vascular, Rubicon Filter -
Rubicon Medical, Spider - ev3, Trap - ev3, Interceptor -
Medtronic], proximal occlusion in 192 (6.4%) [Mo.
Ma - Invatec, Parodi Anti Emboli System - Gore] and
distal occlusion in 26 (0.8%) [Percusurge - Medtronic]
patients.
Closed cell stents (i.e. all stent-struts are intercon-
nected: Carotid Wallstent - Boston Scientific Corp,
Natick, MA, USA; X-act - Abbott Vascular Devices,
Redwood City, CA, USA; NexStent - Endotex, Cuper-
tino, CA, USA) were used in 2242 cases (70.5%) and
open cell stent (i.e. not all stent-struts are intercon-
nected: Precise - Cordis, Miami Lakes, FL, USA;
Exponent - Medtronic Vascular, Santa Rosa, CA,
USA; Prote´ge´ - ev3, Plymouth, MN, USA; Acculink -
Guidant, Santa Clara, CA, USA) implantation was
performed in 937 (29.5%) procedures. Table 2 gives
a detailed overview of the selected stents.
130 patients were intented to be treated without
EPD: 112 received Carotid Wallstent, 7 Acculink, 6
Precise, 3 Prote`ge`, 1 NexStent, 1 X-act. The majority
of these cases dated from the period that no protection
devices were available.
Events where subdivided into procedural (until
removal of all endovascular material) and post-
procedural (until 30 days) events. The distribution ofEur J Vasc Endovasc Surg Vol 33, February 2007T
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137Does Free Cell Area Influence the Outcome in Carotid Artery Stenting?neurological complications were analysed for associa-
tion with the different stents (X-act, Nexstent, Wall-
stent, Precise, Prote´ge´, Acculink, Exponent), different
free cell areas (0e2.5 mm2; 2.5e5 mm2; 5e7.5 mm2
and >7.5 mm2) and different cell design (open versus
closed cell stents).
Medical treatment
Pre-procedure: All patients were treated with acetyl-
salicylic acid (ASA) at a mean dosage of 125 mg/
day, associated with clopidogrel or ticlopidine at
a mean dosage of 75 mg/day or 500 mg/day respec-
tively at least 4e5 days prior to admission.
During the procedure: Weight-adjusted (70 IU/kg)
heparin was administered and repeated as necessary
to maintain an activated clotting time of 225 to 250
seconds throughout the procedure. Atropine (0.5e
1 mg IV) was given to most patients just before the
post-stenting dilation phase in order to reduce the
bradycardia and hypotension potentially associated
with carotid dilation. Atropine was not administered
in patients with tachycardia and uncontrolled
systemic hypertension.
Post procedure: Clopidogrel (75 mg/day) or ticlo-
pidine (500 mg/day) was continued for at least 30
days after the interventional procedure (Haemoglobin
and white blood count were checked 7e10 days
following the percutaneous intervention). Mono
anti-platelet therapy (either aspirin, clopidogrel or
ticlopidine) was continued indefinitely.
Patient assessment
Neurological examinations were performed by an
independent team of neurologists. Prior to treatment
the patients underwent careful neurological examina-
tion (including NIH Stroke Scale), echo/color flow
Table 2. Overview of the selected stents
Type Name N (%)
Closed cell Carotid Wallstent (Boston
Scientific Corp, Natick, MA, USA)
2107 (66.2%)
X-act (Abbott Vascular Devices,
Redwood City, CA, USA)
105 (3.3%)
NexStent (Endotex,
Cupertino, CA, USA)
30 (0.9%)
Open cell Precise (Cordis, Miami Lakes,
FL, USA)
293 (9.2%)
Exponent (Medtronic, Vascular,
Santa Rosa, CA, USA)
34 (1.1%)
Prote´ge´ (ev3, Plymouth, MN, USA) 201 (6.3%)
Acculink (Guidant, Santa Clara,
CA, USA)
409 (12.9%)Doppler (lesion site and intracranial cerebral blood
flow assessment), cerebral CT/MR scan. These tests
were used to determine the degree of stenosis, rule
out coexistent proximal or distal disease, and assess
the lesion for echolucency, thrombus, and ulceration.
All findings were subsequently confirmed by digital
subtraction angiography at the time of CAS.
Within 24 hours of the procedure and at 30 days
post-discharge the patients underwent a neurological
examination and a complete echo/color flow Doppler
evaluation. The neurological complications were de-
fined as death, major stroke (i.e. persisting>24 hours),
minor stroke (i.e. persisting <24 hours) and TIA (i.e.
immediate recuperation of complaints).
A post-procedure cerebral CT/MR scan was
performed only in patients with documented neuro-
logical complications.
Statistical analysis
Comparison of event rates between different groups
was based on Pearson’s Chi-square test whenever
appropriate (i.e. whenever the expected cell counts
exceeded 5 in at least 80% of all cells). Fisher’s exact
test was used in all other cases. The analysis of the
total population was considered as the primary anal-
ysis. To allow for multiple testing, the subgroup and
post-hoc analyses were applied using Bonferoni cor-
rections. All analyses were conducted in SPSS Version
12.0.0.
Results
1. Comparison of event rates between stents
The detailed overview of the complications per stent
are listed in Table 3. Table 4 reports the event rates
related to the different stents for the total population,
symptomatic and asymptomatic subgroups in abso-
lute numbers and percentage. From the 48 compli-
cations that occurred in the group treated with the
Table 3. Detailed overview of the event rates per carotid stent
Device Number Death
(%)
Major
(%)
Minor
(%)
TIA
(%)
Combined
(%)
X-act 105 1,0 0,0 0,0 1,0 1,9
Nexstent 30 0,0 3,3 0,0 0,0 3,3
Wallstent 2107 0,2 0,4 0,6 1,1 2,3
Precise 293 0,7 0,3 0,7 2,4 4,1
Prote´ge´ 201 0,0 0,0 1,5 1,5 3,0
Acculink 409 0,0 0,5 0,7 2,9 4,2
Exponent 34 0,0 0,0 2,9 8,8 11,8
Total 3179 0,2 0,4 0,7 1,5 2,8Eur J Vasc Endovasc Surg Vol 33, February 2007
138 M. Bosiers et al.Table 4. Overview of event rates related to the different stents
Total population Symptomatic population Asymptomatic population
Patients All
events
Post-procedural
events
Patients All
events
Post-procedural
events
Patients All
events
Post-procedural
events
Stent name
X-Act 105 2 2 46 1 1 59 1 1
Nexstent 30 1 1 6 0 0 24 1 1
Wallstent 2107 48 26 882 20 11 1225 28 15
Precise 293 12 9 144 9 7 149 3 2
Prote´ge´ 201 6 6 60 4 4 141 2 2
Acculink 409 17 15 168 13 12 241 4 3
Exponent 34 4 2 11 1 1 23 3 1
Total 3179 90 61 1317 48 36 1862 42 25
Stent name
X-act 1.9% 1.9% 2.2% 2.2% 1.7% 1.7%
Nexstent 3.3% 3.3% 0.0% 0.0% 4.2% 4.2%
Wallstent 2.3% 1.2% 2.3% 1.2% 2.3% 1.2%
Precise 4.1% 3.1% 6.3% 4.9% 2.0% 1.3%
Prote´ge´ 3.0% 3.0% 6.7% 6.7% 1.4% 1.4%
Acculink 4.2% 3.7% 7.7% 7.1% 1.7% 1.2%
Exponent 11.8% 5.9% 9.1% 9.1% 13.0% 4.3%
Total 3179 2.83% 1.9% 1317 3.6% 2.73% 1862 2.25% 1.3%Wallstent, 3 were treated without EPD (1 symptomatic
and 2 asymptomatic). These three patients were
before the year 2000 (no EPD available). All three oc-
curred during the procedure (1 TIA, 2 minor stroke),
and were included in the final analysis.
Table 5 reports p-values for the comparison of event
rates between stents. The primary analysis of the
total population reveals significant differences in
event rates between stents, most obvious for the post-
procedural events.
Highest post-procedural event rates were observed
for Exponent (5.9%), Acculink (3.7%), NexStent (3.3%),
Precise (3.1%) and Prote´ge´ (3.0%). Lowest post-
procedural event rates were observed for Wallstent
(1.2%) and X-act (1.9%). Secondary analyses revealed
that differences in complication rates between
stents were much more pronounced among symptom-
atic patients. However, there was no evidence of
differences between stents in the asymptomatic
population.
We subsequently performed post-hoc analyses to
investigate precisely which stents are different in
terms of event rates. Given that Table 5 revealed no
significant differences in event rates in the asymptom-
atic population, no post-hoc comparisons were per-
formed for this population. Due to small samples
Table 5. P-values for the test that event rates differ between stents
Population Outcome p-value
Total All events 0.018
Post-procedural events 0.002
Symptomatic All events 0.006
Post-procedural events <0.0001
Asymptomatic All events 0.248
Post-procedural events 0.790Eur J Vasc Endovasc Surg Vol 33, February 2007available for each comparison and by the need to ad-
just for multiple testing error, little power is available
for detecting differences in event rates between each
pair of stents. After adjustment for multiple testing,
significant differences could only be established
between Wallstent and Acculink in terms of post-
procedural events for the total population (event rates
1.2% vs 3.7%, p¼ 0.0079), in terms of all events for the
symptomatic patient population (event rates 2.3% vs
7.7%, p¼ 0.0041) and in terms of post-procedural
events for the symptomatic patient population (event
rates 1.2% vs 7.1%, p¼ 3.6 105).
2. Comparison of event rates by free cell area
The different stents where than subdived in 4 sub-
groups according to free cell area:
- <2.5 mm2: Wallstent (1.08 mm2), X-Act (2.74 mm2)
- 2.5e5 mm2: NexStent (4.07 mm2)
- 5e7.5 mm2:Precise (5.89 mm2),Exponent (6.51 mm2)
- >7.5 mm2:Prote´ge´ (10.71 mm2),Acculink(11.48 mm2)
Table 6 reports the values of all and post-procedural
event rates by free cell area in the total, symptomatic
and asymptomatic population. The primary analysis
of the total population reveals significant differences
in event rates according to free cell area, again most
importantly for the post-procedural events. Post-
procedural event rates equal 1.2%, 2.2%, 3.4% and
3.4% for free cell areas lower than 2.5 mm2, between
2.5 mm2 and 5 mm2, between 5 mm2 and 7.5 mm2,
and higher than 7.5 mm2, respectively. A secondary
subgroup analysis shows that differences in
139Does Free Cell Area Influence the Outcome in Carotid Artery Stenting?Table 6. Overview of event rates related to the different free cell area
Total population Symptomatic population Asymptomatic population
Patients All
events
Post-procedural
events
Patients All
events
Post-procedural
events
Patients All
events
Post-procedural
events
Free cell area
<2,5 mm2 2107 48 26 882 20 11 1225 28 15
2,5e5 mm2 135 3 3 52 1 1 83 2 2
5e7,5 mm2 327 16 11 155 10 8 172 6 3
>7,5 mm2 610 23 21 228 17 16 382 6 5
Total 3179 90 61 1317 48 36 1862 42 25
Free cell area
<2,5 mm2 2.3% 1.2% 2.3% 1.2% 2.3% 1.2%
2,5e5 mm2 2.2% 2.2% 1.9% 1.9% 2.4% 2.4%
5e7,5 mm2 4.9% 3.4% 6.5% 5.2% 3.5% 1.7%
>7,5 mm2 3.8% 3.4% 7.5% 7.0% 1.6% 1.3%
Total 3179 2.83% 1.9% 1317 3.6% 2.73% 1862 2.25% 1.3%complication rates are again substantially more pro-
nounced among symptomatic patients. However,
there was no evidence of differences according to
free cell area in the asymptomatic population. Very
similar results were obtained using trend tests which
tend to be more powerful.
Table 7 reports p-values for the test for the associa-
tion of event rates and free cell area.
We subsequently performed post-hoc analyses to
investigate precisely which groups of stents (as de-
fined in terms of free cell area) are different in terms
of event rates. Given that Table 7 revealed no signifi-
cant differences in event rates in the asymptomatic
population, no post-hoc comparisons were performed
for this population. After adjustment for multiple test-
ing important significant differences are observed in
the symptomatic population between stents with
free cell areas lower than 2.5 mm2 on one the hand
and larger than 5 mm2 on the other hand, and this
for both event types (all events and post-procedural
events) (see Table 8). Specifically, all event rates equal
2.3%, 6.5% and 7.5% for free cell areas lower than
2.5 mm2, between 5 mm2 and 7.5 mm2, and higher
than 7.5 mm2, respectively, in the symptomatic patient
population. Post-procedural event rates equal 1.2%,
5.2% and 7.0%, respectively, in that population. Be-
cause these differences get diluted with the absence
of differences in the asymptomatic population,
Table 7. P-values for the test that event rates differ by free cell
area
Population Outcome p-value
Total All events 0.024
Post-procedural events 0.002
Symptomatic All events 0.002
Post-procedural events <0.0001
Asymptomatic All events 1.00
Post-procedural events 1.00differences are much weaker and usually non-signifi-
cant in the total study population.
3. Comparison of event rates by cell types
Table 9 reports values of all and post-procedural event
rates between cell types (open vs. closed) in the total,
symptomatic and asymptomatic population.
The primary analysis of the total population reveals
significant differences in event rates according to cell
type, again especially for the post-procedural events.
Post-procedural event rates were observed to be
1.3% for closed cells and 3.4% for open cells (Table 10).
The secondary analysis shows that differences in
complication rates between cell types are highly pro-
nounced among symptomatic patients, but there
was no evidence of differences between cell types in
the asymptomatic population.
Study Limitation
Although this study involves a large cohort of pa-
tients, it is a retrospective non-randomized analysis.
The majority of the CAS procedures where performed
in the perspective of clinical trials and carotid training
Table 8. P-values for post-hoc comparisons of event rates by free
cell area
Free cell area Total population Symptomatic population
All
events
Post-
procedural
events
All
events
Post-
procedural
events
<2.5 vs [2.5, 5] 1.00 1.00 1.00 1.00
<2.5 vs [5, 7.5] 0.054 0.072 0.048 0.024
<2.5 vs >7.5 0.27 0.006 0.0006 2.8 106
[2.5 e 5] vs [5, 7.5] 1.00 1.00 1.00 1.00
[2.5 e 5] vs >7.5 1.00 1.00 1.00 1.00
[5 e 7.5] vs >7.5 1.00 1.00 1.00 1.00Eur J Vasc Endovasc Surg Vol 33, February 2007
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Total population Symptomatic population Asymptomatic population
Patients All
events
Post-procedural
events
Patients All
events
Post-procedural
events
Patients All
events
Post-procedural
events
Open cell 937 39 32 383 27 24 554 12 8
Closed cell 2242 51 29 934 21 12 1308 30 17
Total 3179 90 61 1317 48 36 1862 42 25
Cell type
Open cell 4.2% 3.4% 7.0% 6.3% 2.2% 1.4%
Closed cell 2.3% 1.3% 2.2% 1.3% 2.3% 1.3%
Total 3179 2.83% 1.9% 1317 3.6% 2.73% 1862 2.25% 1.3%programs sponsored by different companies. During
these sessions the interventions where performed
with the sponsor’s device, except for cases presenting
with extreme anatomy (example: open cell flexible
stent in tortuous bifurcation or closed cell stent in
plaques considered as vulnerable). So even though
one could argue that devise selection was biased,
the majority of the stents where assigned randomly.
Discussion
The nature of most neurological events in patients
with carotid artery stenosis are not related to hypo-
perfusion of the brain but have an emboligenic origin.
As demonstrated in multi-center prospective ran-
domized trials,10e14 carotid endarterectomy (CEA),
removing the plaque and the source of emboli, is the
gold standard to reduce stroke in symptomatic
and asymptomatic patients with significant carotid
stenosis.15e16
An effective endovascular approach should conse-
quently either be able to remove the plaque com-
pletely or prevent it from embolization. The CAS
procedure as performed now17 opens the stenosis by
dilatation and tries to prevent future embolization
through the scaffolding of the ruptured plaque
against the vessel wall by means of a stent. Therefore
after completion of the procedure the struts of the
stent are the only protection against post-procedural
neurological events.18e20
Table 10. P-values for the test that event rates differ by cell type
Population Outcome p-value
Total All events 0.005
Post-procedural events <0.0001
Symptomatic All events <0.0001
Post-procedural events <0.0001
Asymptomatic All events 1.00
Post-procedural events 1.00Eur J Vasc Endovasc Surg Vol 33, February 2007The results of our retrospective statistical analysis
suggest that especially in symptomatic patient, who
are known to have an emboligenic plaque,21 the
choice of a stent with a small free cell area resulted
in a significant decrease of the post-procedural events.
In the symptomatic population free cell area was a sig-
nificant predictor of the number of events (all events:
p¼ 0.002 and post-procedural events p< 0.0001). A
free cell area lower than 2.5 mm showed superiority
for both event types (all and post-procedural events)
(<2.5 vs. 5e7.5; all: p¼ 0.048 e post-procedural:
p¼ 0.024 and <2.5 vs. >7.5; all: p¼ 0.0006; post-
procedural: p¼ 2.8 106). Significant differences could
also be established between the stent with the smallest
free cell area (Wallstent: 1.08 mm2) and the one with
the largest free cell area (Acculink: 11.48 mm2) in
terms of all events for the total population
( p¼ 0.0079) and all ( p¼ 0.0041) as well as post-
procedural ( p¼ 3.6 105) events in the symptomatic
population.
Comparing stents by cell types (open vs. closed) in
the total (3.4% vs. 1.3%) and most of all in the symp-
tomatic population (6.3% vs. 1.3%) resulted in a clear
reduction of predominantly post-procedural events
for the closed cell group.
In the asymptomatic population free cell area or
cell type did not influence the event rate. The 30-day
stroke and death rate for the asymptomatic group
(42 events in 1862 patients: 2.2%) was considerably
lower than in the symptomatic patients (48 events in
1317 patients: 3.6%).
In contrast with many single high volume centers
who have reported low intra- and post-procedural ad-
verse neurologic events after CAS,22e25 recent update
from randomized multi-center trial suggest higher
rates of complications. The EVA-3S26 and SPACE27
trials reported poor results for CAS in symptomatic
patients: stroke and death rate at 30 days respectively
9.6% and 6.8%. In these trials many different stents
have been used. A sub-analysis of these trial results
comparing free cell area with event rate could be of
141Does Free Cell Area Influence the Outcome in Carotid Artery Stenting?interest to find a possible explanation for the high
complication rate.
Conclusions
We conclude that there is substantial evidence for dif-
ferences in complication rates between stents
( p¼ 0.002 for the late events). This is almost entirely
explained by differences in event rates in the symp-
tomatic population as no important differences could
be established in the asymptomatic population. In the
symptomatic population late complication rates are
highest for the open cell types and increase with
larger free cell area. Prospective randomised trials
comparing different free cell areas should be con-
ducted in order to further investigate this question.
For the time being consideration should be given to
the use of stents with a small free cell area especially
in symptomatic patients.
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